REGULATORY
Posaconazole Added to List of Azole Antifungals Contraindicated for Xarelto on Bleeding Risks
The Ministry of Health, Labor and Welfare (MHLW) has strengthened safety measures for Bayer’s anticoagulant Xarelto (rivaroxaban), with the drug’s label revised to contraindicate its use together with the azole antifungal posaconazole. According to the MHLW, various azole antifungal agents…
To read the full story
REGULATORY
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
- Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
- LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
- Three Sent to Prosecutors over Alleged Illegal Mounjaro Sales
June 3, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





